Zolmitriptan (CAS No.: 139264-17-8)
Manus Aktteva Biopharma LLP, a global supplier of Zolmitriptan, 139264-17-8 offers for your requirements of RND / Development quantities or commercials, based on status of the product. We can also offer its intermediates with supportive technical package required for evaluation.
CAS number:
139264-17-8
Chemical Name:
(4R)-4-[[3-(2-Dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one, Zolmitriptan (CAS No.: 139264-17-8)
Pharmacopeia:
USP, EP, In House
Certificate:
GMP, cGMP, EUGMP, WHO GMP, ISO Certified, USFDA, Cofepris Mexico, Korea FDA
Application:
For R&D Purpose
Email To:
Your Email:
Your Name:
Note:
Processing....
Synonym
(4R)-4-[[3-(2-Dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one, Zolmitriptan (CAS No.: 139264-17-8)
Specifications
Available on request
Packing
Export worthy packing
Material Safety Data Sheet
Available on request
Availability
FOR R&D PORPOSE ONLY
Product Name |
CAS No. |
|
(S)-4-(4-Aminobenzyl)-2(1H)-oxazolidinone |
152305-23-2 |
View | Inquire |
L-4-Nitrophenylalanine methyl ester hydrochloride |
17193-40-7 |
View | Inquire |
(S)-4-Benzyl-2-oxazolidinone |
90719-32-7 |
View | Inquire |
(S)-4-(4'-Nitrobenzyl)-1,3-oxazolidine-2-one |
139264-66-7 |
View | Inquire |
4,4-Diethoxy-N,N-dimethyl-1-butanamine |
1116-77-4 |
View | Inquire |
Sodium 4-chloro-1-hydroxybutanesulfonate |
54322-20-2 |
View | Inquire |
4-Nitro-L-phenylalanine monohydrate |
207591-86-4 |
View | Inquire |
N-(4-Methoxy-2-methylquinolin-6-yl)acetamide |
100795-23-1 |
View | Inquire |
4,6-Diamino-2-Methyl-Quinoline |
5443-31-2 |
View | Inquire |
Description:
Zolmitriptan : Anti Migraine - is used for the acute treatment of migraines with or without aura in adults. Zolmitriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine.
- Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk.
- Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271 +A13(1)
- Products falling in to controlled substance category / list of schedule drugs shall be exported directly from the manufacturer principals only against receipt of original import permission issued by concerned authorities of the importing country.
- Manus Aktteva Biopharma LLP assumes no responsibility/liability in case of being imparted with goods which infringe intellectual property in any manner whatsoever which includes patent rights of any individual. Manus Aktteva makes no representations or warranties of any kind, express or implied, about the originality or reliability with respect to the intellectual property which includes patents in its products or services for any purpose.
- Manus Aktteva Biopharma LLP warns the sellers not to sell any goods which infringe intellectual property in any manner whatsoever which includes patent rights of any individual.
- Manus Aktteva Biopharma LLP warns the buyers not to use/procure any goods to achieve a product which might be knowingly causing an infringement of intellectual property in any manner whatsoever which includes patent rights of any individual.
Are you looking for Zolmitriptan (CAS No.: 139264-17-8) with documentation like PMDA - JAPAN, DMF - CANADA, TGA - AUSTRALIA, DMF (CLOSED PART), MHRA - UK, DMF - KOREA, AIFA - ITALY, MEDSAFE - NEW ZEALAND, HEALTH CANADA, JDMF, JAPAN - AFM, DCGI, COPP, TDMF, Written Confirmation? Please
click here to send us sourcing request.
Zolmitriptan, 139264-17-8, USDMF, EDMF, CEP / COS, DMF (OPEN PART), TDP, DMF - CTD, ICH, GMP, cGMP, EUGMP, WHO GMP, ISO Certified, USFDA, Cofepris Mexico, Korea FDA, Price, Cost, Manufacturer, Exporter, Supplier, India, China, MSDS
Queries
Easy ways to get the answers you need.
+91 79 26463394
+91 79 26463395